Use of capecitabine in management of early colon cancer

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 295-299

  Hameed, H ^a   Cassidy, J ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

5 fluorouracil; 5 FU; FOLFOX; Folinic acid; Leucovorin; LV; Oxaliplatin; XELOX

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MICROSATELLITE DNA; OXALIPLATIN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DNA SYNTHESIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LOW DRUG DOSE; MICROSATELLITE INSTABILITY; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; STOMATITIS; VOMITING;

EID: 80955124123     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Gray RF, Brewster DH, Kidd J, Burns H. Colorectal cancer in Scotland: recent trends in incidence and mortality. Gastrointest Oncol. 2002;4:213-222.
2. Hayne D, Brown R, McCormack M, et al. Current trends in colorectal cancer: site, incidence, mortality and survival in England and Wales. Clin Oncol. 2001;13:448-452.
3. Office for National Statistics. Cancer statistics - registrations, England, 2006. Series MB1 no. 37. London, UK: Office for National Statistics; 2008.
4. National Cancer Intelligence Network. Colorectal cancer survival by stage - NCIN Data Briefing. 2009 Jun. Available from: http://www.ncin.org.uk/publications/data_briefings/colorectal_cancer_survival_by_stage.aspx. Accessed August 1, 2011.
5. Dukes CE. The classification of cancer of the rectum. J Pathol. 1932;35:323-332.
6. Beahrs OH, Henson DE, Hutter DE, et al. Manual for Staging of Cancer. 3rd ed. Philadelphia: Lippincott; 1988.
7. Edge SB, Byrd DR, Compton CC, et al. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 7th ed. Springer, New York; 2010:143.
8. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher dose folinic acid or both as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet. 2000;355:1588-1596.
9. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663-666.
10. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol. 1992;10:896-903.
11. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-358.
12. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939-944.
13. Carrato A, Kohne C, Bedenne L, et al. Folinic acid modulated bolus 5-FU or infusional 5-FU treatment of patients of UICC stage III colon cancer: preliminary analysis of the PETACC-2-study. Proc ASCO. 2006;24(18 Suppl):161s.
14. Goldberg R. Oxaliplatin in colorectal cancer: current studies. Oncology (Williston Park). 2000;14(12 Suppl 11):42-47.
15. Schmoll HJ, Cassidy J. Integrating oxaliplatin into the management of colorectal cancer. Oncologist. 2001;6 (Suppl 4):24-28.
16. André T, Boni C, Mounedji-Boudiaf L, et al; for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
17. Fraile RJ, Baker LH, Buroker TR, et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res. 1980;40:2223-2228.
18. Milano G, Schellens JHM. Pyrimidine antimetabolites. In: Schellens JHM, McLeod HL, Newell DR, editors. Cancer Clinical Pharmacology. Oxford: University Press; 2005:51-62.
19. Xu Y, Grem JL. Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma. J Chromatogr B Biomed Appl. 2003;783:273-285.
20. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res. 1998;4:941-948.
21. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer. 2006;94:1122-1129.
22. Van Cutsem E, Hoff P, Harper P, et al. Oral capecitabine versus intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90:1190-1197.
23. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25:102-109.
24. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol. 2010:28(Suppl abstr CRA3507):262s.
25. Roche. Roche provides results on Avastin in adjuvant colon cancer [Press release 2010 Sep 18]. Roche, Basel, Switzerland.
26. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011:29:11-16.
27. Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer. 2001:37:597-604.
28. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-257.
29. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2007;25:767-772.
30. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 27:3117-3125.